| Name: AMIDEX Cancer Innovations & Healthcare Index
Code: CNCRX
Description: The AMIDEX Cancer Index is an equity benchmark for Pharmaceutical, Biotechnology and Medical Equipment companies that emphasize cancer detection, prevention or treatment.
Rationale: The AMIDEX Cancer Innovations & Healthcare Index is the first benchmark for one of the most significant sub-sectors of the healthcare industry -
The companies emphasize cancer detection and treatment.
Background: Today, about half of the 1,000 medicines in human clinical testing are cutting-edge drugs targeted at forms of cancer, the second leading killer of Americans.
So far, 76 biotechnology drugs, most developed by private sector companies, have been approved for marketing. Many of the new products are safer and more effective than the older chemical compounds used for treatment.
Expenditures by the private sector for research and development of new diagnostic tools and innovative treatments continue to grow. Companies will spend over $26.4 billion this year on research and development, more than 5 times the amount of such expenditures by the government.
Methodology: The AMIDEX Cancer Innovations & Healthcare Index is an enhanced market capitalization weighted index, consisting of the 45 highest capitalized Pharmaceutical, Bio-Tech and Medical Equipment companies publicly traded on U.S. exchanges.
|
